Ekopipam
(Preusmjereno sa stranice DMJWENQHWZZWDF-PKOBYXMFSA-N)
Ekopipam (SCH-39166) je sintetički benzazepinski derivat. Ovaj lek deluje kao selektivni antagonist D1/D5 receptora, sa neznatnim afinitetom za bilo D2-slične ili 5-HT2 receptore.[3] On ispoljava sedativno, antipsihotičko i anoreksno dejstvo. Ovaj lek je bio ispitivan za moguću primenu na ljudima, mada nije odobren zbog nuspojava, kao što su depresija i anksioznost.[4][5]
| |||
| (IUPAC) ime | |||
|---|---|---|---|
| (–)-trans-6,7,7a,8,9,13b-heksahidro-3-hloro-2-hidroksi-N-metil-5H-benzo[d]napto-(2,1-b)azepin | |||
| Klinički podaci | |||
| Identifikatori | |||
| CAS broj | 112108-01-7 | ||
| ATC kod | nije dodeljen | ||
| PubChem[1][2] | 107930 | ||
| UNII | 0X748O646K 
| ||
| Hemijski podaci | |||
| Formula | C19H20ClNO | ||
| Mol. masa | 313,821 g/mol | ||
| SMILES | eMolekuli & PubHem | ||
| |||
| Farmakoinformacioni podaci | |||
| Trudnoća | ? | ||
| Pravni status | |||
Hemijska sinteza uredi
Ekopipam se može sintetisati iz jednostavnog derivata tetralina:[6]
Reference uredi
- ↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.
- ↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
- ↑ Chipkin RE, Iorio LC, Coffin VL, McQuade RD, Berger JG, Barnett A (December 1988). „Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity”. The Journal of Pharmacology and Experimental Therapeutics 247 (3): 1093–102. PMID 2905002.
- ↑ Hou D, Schumacher D (November 2001). „The selection of a commercial route for the D1 antagonist Sch-39166”. Current Opinion in Drug Discovery & Development 4 (6): 792–9. PMID 11899619.
- ↑ Astrup A, Greenway FL, Ling W, Pedicone L, Lachowicz J, Strader CD, Kwan R (July 2007). „Randomized controlled trials of the D1/D5 antagonist ecopipam for weight loss in obese subjects”. Obesity (Silver Spring, Md.) 15 (7): 1717–31. DOI:10.1038/oby.2007.205. PMID 17636090.
- ↑ Hou, D; Schumacher, D (2001). „The selection of a commercial route for the D1 antagonist Sch-39166.”. Current opinion in drug discovery & development 4 (6): 792–9. PMID 11899619.
